SCD and MTHFD2 inhibitors for high‐risk acute myeloid leukaemia patients, as suggested by ELN2017‐pathway association

Detalles Bibliográficos
Autores principales: Kim, Han Sun, Kim, Doyeon, Kim, Jiwoo, Park, Sunghyouk, de Guzman, Arvie Camille V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307990/
https://www.ncbi.nlm.nih.gov/pubmed/37381167
http://dx.doi.org/10.1002/ctm2.1311
_version_ 1785066150376243200
author Kim, Han Sun
Kim, Doyeon
Kim, Jiwoo
Park, Sunghyouk
de Guzman, Arvie Camille V.
author_facet Kim, Han Sun
Kim, Doyeon
Kim, Jiwoo
Park, Sunghyouk
de Guzman, Arvie Camille V.
author_sort Kim, Han Sun
collection PubMed
description
format Online
Article
Text
id pubmed-10307990
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-103079902023-06-30 SCD and MTHFD2 inhibitors for high‐risk acute myeloid leukaemia patients, as suggested by ELN2017‐pathway association Kim, Han Sun Kim, Doyeon Kim, Jiwoo Park, Sunghyouk de Guzman, Arvie Camille V. Clin Transl Med Letter to the Editor John Wiley and Sons Inc. 2023-06-28 /pmc/articles/PMC10307990/ /pubmed/37381167 http://dx.doi.org/10.1002/ctm2.1311 Text en © 2023 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to the Editor
Kim, Han Sun
Kim, Doyeon
Kim, Jiwoo
Park, Sunghyouk
de Guzman, Arvie Camille V.
SCD and MTHFD2 inhibitors for high‐risk acute myeloid leukaemia patients, as suggested by ELN2017‐pathway association
title SCD and MTHFD2 inhibitors for high‐risk acute myeloid leukaemia patients, as suggested by ELN2017‐pathway association
title_full SCD and MTHFD2 inhibitors for high‐risk acute myeloid leukaemia patients, as suggested by ELN2017‐pathway association
title_fullStr SCD and MTHFD2 inhibitors for high‐risk acute myeloid leukaemia patients, as suggested by ELN2017‐pathway association
title_full_unstemmed SCD and MTHFD2 inhibitors for high‐risk acute myeloid leukaemia patients, as suggested by ELN2017‐pathway association
title_short SCD and MTHFD2 inhibitors for high‐risk acute myeloid leukaemia patients, as suggested by ELN2017‐pathway association
title_sort scd and mthfd2 inhibitors for high‐risk acute myeloid leukaemia patients, as suggested by eln2017‐pathway association
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10307990/
https://www.ncbi.nlm.nih.gov/pubmed/37381167
http://dx.doi.org/10.1002/ctm2.1311
work_keys_str_mv AT kimhansun scdandmthfd2inhibitorsforhighriskacutemyeloidleukaemiapatientsassuggestedbyeln2017pathwayassociation
AT kimdoyeon scdandmthfd2inhibitorsforhighriskacutemyeloidleukaemiapatientsassuggestedbyeln2017pathwayassociation
AT kimjiwoo scdandmthfd2inhibitorsforhighriskacutemyeloidleukaemiapatientsassuggestedbyeln2017pathwayassociation
AT parksunghyouk scdandmthfd2inhibitorsforhighriskacutemyeloidleukaemiapatientsassuggestedbyeln2017pathwayassociation
AT deguzmanarviecamillev scdandmthfd2inhibitorsforhighriskacutemyeloidleukaemiapatientsassuggestedbyeln2017pathwayassociation

Ejemplares similares